RxDoctor Payments Data

Archana Srinivas, MD

Rheumatology · Nashville, TNNPI 1063705432

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,006 of the $2,282 with a category attached, or 87.9%. 16 manufacturers reported payments, led by Amgen at 32.0% of the total. Reporting peaked in 2023 at $645 and has fallen 81.1% since, to $122 in 2024. That places this record below the midpoint for rheumatology clinicians in TN, where the typical reported total is $5,288.

$2,282in general payments, 2019–2025

Across 109 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$731
  • Johnson & Johnson$346
  • Novartis$326
  • GSK$158
  • AstraZeneca$141
  • E.r. Squibb & Sons, L.L.C.$136
  • plus $445 from 10 others

What the payments were for

  • Consulting fees$402%
  • Food & beverage$2,00688%
  • Education$23610%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,282 in reported general payments places this provider in the 40th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee →

Medicare billing

Part B allowed, 2024
$342,130
Medicare patients
175
Services billed
21,760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$208,310
Taltz AutoinjectorIxekizumab21$190,127
Enbrel SureclickEtanercept12$100,532
Evenity (2 Syringes)Romosozumab-Aqqg11$27,242
ProliaDenosumab15$26,453
RasuvoMethotrexate/Pf12$7,715
Hydroxychloroquine Sulfate130$5,170
MethotrexateMethotrexate Sodium112$3,189
Pilocarpine Hcl13$2,289
Risedronate Sodium23$1,283
Diclofenac Sodium13$1,267
Sulfasalazine DrSulfasalazine26$1,244
Leflunomide40$1,032
Allopurinol20$499
Prednisone48$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEvenity (2 Syringes), Prolia$731$53,69626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 127 rheumatology providers in Tennessee.

Other rheumatology in Nashville

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →